26/06/2021

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS CoV-2 infection and related severe COVID-19.

Matéria Original

Anterior

Prediction and identification of T cell epitopes of COVID-19 with balanced cytokine response for the development of peptide based vaccines
Próxima

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques